The discovery of DNA damage-p53-AKT pathway provides strong rationale for treating ALT cancers that express wt-p53 with agents that inhibit p53 and/or AKT without concomitant exposure to DNA damaging agents (Fig. 6). This evidence concerns the gene TP53 and cancer.